全球生物製藥市場：市場規模和佔有率分析 - 趨勢、驅動因素、競爭格局和預測（2024-2030）

主要亮點

2023年全球生物製藥市場規模將達4,481億美元，2030年將達7,451億美元，複合年增長率超過7.4%。生物製藥的研發和治療接受度的提高正在推動產業擴張。

自推出抗 TNF 生物相似藥以來，歐洲的平均成本已降低約 8%，G-CSF 和促紅血球生成素生物相似藥則降低了 33-34%。這有助於生物製藥獲得廣泛接受。生物製藥的功效和安全性已迅速被大眾接受。

許多組織和公司都專注於與生物製藥相關的研發，每年的NDA/BLA註冊數量都在大幅增加。特別是，由於傳染病、神經系統疾病和癌症的增加，生物製藥的重要性日益增加。

市場洞察

2023 年，北美地區佔該產業最大佔有率，約 45%。

這是由於研發資金的可用性、技術改進解決方案的接受度提高、國際公司的存在以及對獲得新專利的重視。美國在該大陸引領該產業。

2023年，腫瘤領域將引領產業，約佔40%佔有率。近年來，生物製藥在癌症試驗中佔據主導地位，超過了非癌症疾病試驗。

未來幾年，細胞和基因治療將以最快的複合年增長率成長。該領域已經取得了一些進展，先進的研究應用於各種治療領域的臨床試驗，包括細胞和基因治療以及精準藥物等標靶治療。

單株抗體將在2023年佔據產業最大佔有率，達到35%，並在這十年內以約7.2%的CAGR進一步提升。單株抗體 (mAb) 是最重要的一類生物製劑，佔 FDA 核准的治療候選藥物的 20% 以上。一些單株抗體被批准用於抗發炎、抗癌和其他治療用途。正是由於它廣泛應用於癌症治療，在英國、美國等已開發國家越來越受歡迎。

本報告分析了全球生物製藥市場，包括市場的基本結構和最新情況、主要促進和限制因素以及全球、依地區和主要國家的市場規模（數量和金額）前景。依產品類型和治療用途劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依治療應用分類（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依治療應用分類（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第十一章中東非洲市場

第12章美國市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依治療應用劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第28章阿聯酋市場

第29章競爭態勢

• 市場參與者及其產品列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Johnson & Johnson Inc.
• F. Hoffmann-La Roche AG
• Pfizer Inc
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Eli Lilly and Company
• Abbott Laboratories
• AstraZeneca plc
• Novartis AG
• Biogen Inc.

第31章附錄

Key Highlights

The biopharmaceutical market generated a value of USD 448.1 billion in 2023, which will rise to USD 745.1 billion, powering at more than 7.4% compound annual growth rate, by 2030.

The surging elderly populace, the incidence of associated health problems, and the rising need for better biologic drugs are likely to create a healthy growth environment for the players.

The rising research and development as well as therapeutic acceptance of bio-based medications are driving industry expansion.

Since the introduction of biosimilars for anti-TNF products, average costs in Europe have reduced by around 8%, while biosimilars for G-CSF and erythropoietin have reduced by 33-34%.

This has aided the extensive acceptance of biopharmaceuticals. The effectiveness and safety of bio-based medications have resulted in their quick acceptance by people.

Many organizations and businesses are concentrating on R&D related to biological drugs. The number of NDAs/ BLAs registered per year has significantly increased.

With the increasing incidence of infectious diseases, neurological disorders, and cancer, the importance of biopharmaceuticals is rising.

They are utilized for treating neurodegenerative disorders, many of which necessitate bio-medications to be administered into the brain directly, which is not possible with conventional synthetic agents.

Market Insights

North America accounted for the largest share of the industry in 2023, of approximately 45%.

This is because of the high R&D funding, increasing acceptance of technologically improved solutions, the existence of international players, and their emphasis on coming up with newer patents. The U.S. led the industry in this continent.

With the development of conventional pharma sciences and biotechnology, the consciousness about the best treatments with fewer side effects has also surged.

The U.S. leads the worldwide biopharmaceutical research and development list with over 150,000 studies performed since 2008, due to the size and prominence of its pharmaceutical industry.

In the U.S., California accounts for the most studies, partly, due to its strong tech sector as well as its desire for innovation.

Oncology led the industry in 2023, with a share of approximately 40%. In the past few years, biopharmaceuticals have been dominant in cancer trials than trials for non-cancer conditions.

Cell and gene therapies will grow at the fastest compound annual growth rate in the years to come.

There have been several improvements in this area, representing advanced research, which is being employed in clinical trials in different therapeutic fields, such as cell & gene therapies and targeted therapies like precision drugs.

Monoclonal antibodies accounted for the largest share of the industry in 2023, of 35%, and it will further propel at approximately 7.2% CAGR during this decade.

Monoclonal antibodies (mAbs) are the most significant class of biologics, which account for over 20% of all the therapeutic candidates approved by the FDA.

Some mAbs have been permitted for anti-inflammatory, anti-cancer, and additional therapeutic applications. Precisely, because of their widespread utilization in cancer treatment, they are becoming widespread in developed nations like the U.K. and the U.S.

The biopharmaceutical industry is characterized by strong competition among mid-sized firms, large global firms, and new biotech firms.

Major factors boosting the competition are innovative R&D, regulatory compliance, market access, and product differentiation.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by therapeutic application
  • 1.4.3. Market size breakdown, by region
  • 1.4.4. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Therapeutic Application (2017-2030)
• 6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Therapeutic Application (2017-2030)
• 7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Therapeutic Application (2017-2030)
• 8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Therapeutic Application (2017-2030)
• 9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Therapeutic Application (2017-2030)
• 10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Therapeutic Application (2017-2030)
• 11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Johnson & Johnson Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. F. Hoffmann-La Roche AG
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Pfizer Inc
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Merck & Co. Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. AbbVie Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Sanofi SA
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Eli Lilly and Company
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Abbott Laboratories
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. AstraZeneca plc
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Novartis AG
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Biogen Inc.
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports